Sarepta Therapeutics CSO Louise Rodino-Klapac receives $7.3M in 2020
Sarepta Therapeutics reports 2020 executive compensation
By ExecPay News
Published: April 20, 2021
Sarepta Therapeutics reported fiscal year 2020 executive compensation information on April 20, 2021.
In 2020, eight executives at Sarepta Therapeutics received on average a compensation package of $3.5M, a 13% decrease compared to previous year.
Average pay of disclosed executives at Sarepta Therapeutics
Louise Rodino-Klapac, Chief Scientific Officer, received $7.3M in total. 79% of Rodino-Klapac's compensation, or $5.8M, was in option awards. Rodino-Klapac also received $230K in non-equity incentive plan, $496K in salary, $767K in stock awards, as well as $14K in other compensation.
For fiscal year 2020, the median employee pay was $275,247 at Sarepta Therapeutics. Therefore, the ratio of Louise Rodino-Klapac's pay to the median employee pay was 26 to one.
David Tyronne Howton, Jr, General Counsel, received a compensation package of $5.7M, which increased by 36% compared to previous year. 67% of the compensation package, or $3.8M, was in option awards.
Ian M. Estepan, Chief Financial Officer, earned $5.2M in 2020.
Gilmore O'Neill, M.B., M.M.Sc, Chief Scientific Officer, received $3.8M in 2020, which decreases by 27% compared to 2019.
Sandesh Mahatme, Chief Financial Officer, earned $3.4M in 2020, a 35% decrease compared to previous year.
Douglas Ingram, Chief Executive Officer, received $1.3M in 2020, which decreases by 7% compared to 2019.
Joseph Bratica, Vice President, Corporate Controller, earned $912K in 2020.
William Ciambrone, Executive Vice President, Technical Operations, received $680K in 2020, which decreases by 84% compared to 2019.
Related executives
Douglas Ingram
Sarepta Therapeutics
Chief Executive Officer
Ian Estepan
Sarepta Therapeutics
Chief Financial Officer
Gilmore MMSc
Sarepta Therapeutics
Chief Scientific Officer
William Ciambrone
Sarepta Therapeutics
Executive Vice President, Technical Operations
Louise Rodino-Klapac
Sarepta Therapeutics
Chief Scientific Officer
Joseph Bratica
Sarepta Therapeutics
Vice President, Corporate Controller
Sandesh Mahatme
Sarepta Therapeutics
Chief Financial Officer
David Howton
Sarepta Therapeutics
General Counsel
You may also like
Source: SEC filing on April 20, 2021.